This work is licensed under a Creative Commons Attribution 4.0 International License.
ACP52C
General Information
DRACP ID DRACP01178
Peptide Name ACP52C
Sequence NYPQRPCRGDKGPDC
Sequence Length 15
UniProt ID Not available
PubChem CID Not available
Origin Not available
Type Synthetic peptide
Classification
Active ACP
Activity Information
| Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
|---|---|---|---|---|---|---|
| U-251MG | Astrocytoma | Carcinoma | GI50| MTT assay |
Not available |
Patent |
|
| U-343MG | Glioblastoma | Blastoma | GI50| MTT assay |
Not available |
Patent |
|
| MDA-MB-231 | Breast adenocarcinoma | Carcinoma | GI50| MTT assay |
Not available |
Patent |
|
| U-87MG ATCC | Glioblastoma | Blastoma | GI50| MTT assay |
Not available |
Patent |
|
| U-373MG ATCC | Astrocytoma | Carcinoma | GI50| MTT assay |
Not available |
Patent |
|
| HEL | Erythroleukemia; Acute erythroid leukemia | Leukemia | GI50>lg1 μM, as show in fig1 | MTT assay | Not available | Patent |
| K562 | Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia | Leukemia | GI50>lg1 μM, as show in fig1 | MTT assay | Not available | Patent |
| HL-60 | Adult acute myeloid leukemia; Acute myeloid leukemia | Leukemia | GI50| MTT assay |
Not available |
Patent |
|
| Hep 3B2.1-7 | Childhood hepatocellular carcinoma; Pediatric hepatocellular carcinoma | Carcinoma | GI50| MTT assay |
Not available |
Patent |
|
| Hep-G2 | Hepatoblastoma; Hepatoblastoma | Blastoma | GI50| MTT assay |
Not available |
Patent |
|
| MCF-7/CD24KD | Breast cancer | Carcinoma | GI50| MTT assay |
Not available |
Patent |
|
| MCF-7 | Invasive breast carcinoma of no special type | Carcinoma | GI50| MTT assay |
Not available |
Patent |
|
| U-937 | Adult acute monocytic leukemi; Acute monoblastic/monocytic leukemia | Leukemia | GI50| MTT assay |
Not available |
Patent |
|
| HT-29 | Colon adenocarcinoma | Carcinoma | GI50| MTT assay |
Not available |
Patent |
|
| HCT 116 | Colon carcinoma | Carcinoma | GI50| MTT assay |
Not available |
Patent |
|
| Jurkat | Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia | Leukemia | GI50| MTT assay |
Not available |
Patent |
|
| CCRF-CEM | Childhood T acute lymphoblastic leukemia; Precursor T-cell acute lymphoblastic leukemia | Leukemia | GI50| MTT assay |
Not available |
Patent |
|
| MEL | Murine Erythroleukemia | Leukemia | GI50| MTT assay |
Not available |
Patent |
|
| THP-1 | Childhood acute monocytic leukemia; Acute monoblastic/monocytic leukemia | Leukemia | GI50| MTT assay |
Not available |
Patent |
|
| HCC827 | Lung adenocarcinoma | Carcinoma | GI50| MTT assay |
Not available |
Patent |
|
| KCL-22 | Chronic myelogenous leukemia; Chronic myeloid leukemia | Leukemia | GI50| MTT assay |
Not available |
Patent |
|
| A549 | Lung adenocarcinoma | Carcinoma | GI50| MTT assay |
Not available |
Patent |
|
| PC-9 | Lung adenocarcinoma | Carcinoma | GI50| MTT assay |
Not available |
Patent |
|
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity MSC and BEAS-2B: GI50
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer; Antitumor
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Chiral L
Physicochemical Information
Formula C69H108N24O23S2
Absent amino acids AEFHILMSTVW
Common amino acids P
Mass 195578
Pl 8.22
Basic residues 3
Acidic residues 2
Hydrophobic residues 0
Net charge 1
Boman Index -6071
Hydrophobicity -192
Aliphatic Index 0
Half Life
Mammalian: 20 hour
Yeast: 30 min
E.coli: >10 hour
Extinction Coefficient cystines 1615
Absorbance 280nm 115.36
Polar residues 6
Amino acid distribution
Literature Information
Literature 1
Pubmed ID Not available
Title Not available
Doi Not available
Year Not available
Patent
Patent ID KR20200116394A
Patent Title CP2c Anticancer peptide for targeting CP2c
Other Iinformation Patent Application; Family: 2s / 4ex; Family Jurisdictions: KR; Legal Status: Active; Application No: 20190085790; Filed: Jul 16, 2019; Published: Oct 12, 2020; Earliest Priority: Apr 1, 2019; Granted: Jun 8, 2021
Other Published ID KR102261371B1
This work is licensed under a Creative Commons Attribution 4.0 International License.